Artificial Intelligence for Drug Discovery Accelerating the Development of New Pharmaceuticals

AI’s emergence in drug discovery will transform diagnostics, allow accelerated drug development, and realize personalized medicine. However, despite its potential, current AI can cause several challenges, including small-scale validation, AI bias, data privacy, regulatory compliance, as well as scalability and integration into clinical practice. These challenges can be addressed through large-scale real-world validations, fairness-aware algorithms and privacy-preserving techniques building a next-gen AI framework enabling our research. We literally build them in systems to provide transparency with the XAI, scale them up for various healthcare ecosystems, and also work compliant globally with policies like HIPAA, and GDPR. Through the efforts of, you know, we want to try and use various datasets, and embed AI into existing healthcare infrastructures, and apply AI drug discovery to real world patients. Thus, this approach will shorten drug development timelines, reduce healthcare costs, and improve quality of life for patients through more effective personalized treatment options. Basically, our research ties our ethical, transparent and scalable AI-controlled healthcare system to the realization of new digital medicines and universal access to healthcare worldwide.

Authors

Publication Details

Journal
Springer Link (Chiba Institute of Technology)
Published
2025-03-25
DOI
https://doi.org/10.1051/itmconf/20257601010/pdf
Primary Topic
Machine Learning in Healthcare
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Artificial Intelligence for Drug Discovery Accelerating the Development of New Pharmaceuticals

Aparna Kulkarni, Yamini Supriya B, A. Buckshumiyan, Kavya R V et al.
Springer Link (Chiba Institute of Technology)
Machine Learning in Healthcare
article

Artificial Intelligence for Drug Discovery Accelerating the Development of New Pharmaceuticals

Aparna Kulkarni, Yamini Supriya B, A. Buckshumiyan, Kavya R V, T. Syeda Jeelani Basri, Renuka K
article en

Abstract

AI’s emergence in drug discovery will transform diagnostics, allow accelerated drug development, and realize personalized medicine. However, despite its potential, current AI can cause several challenges, including small-scale validation, AI bias, data privacy, regulatory compliance, as well as scalability and integration into clinical practice. These challenges can be addressed through large-scale real-world validations, fairness-aware algorithms and privacy-preserving techniques building a next-gen AI framework enabling our research. We literally build them in systems to provide transparency with the XAI, scale them up for various healthcare ecosystems, and also work compliant globally with policies like HIPAA, and GDPR. Through the efforts of, you know, we want to try and use various datasets, and embed AI into existing healthcare infrastructures, and apply AI drug discovery to real world patients. Thus, this approach will shorten drug development timelines, reduce healthcare costs, and improve quality of life for patients through more effective personalized treatment options. Basically, our research ties our ethical, transparent and scalable AI-controlled healthcare system to the realization of new digital medicines and universal access to healthcare worldwide.

Springer Link (Chiba Institute of Technology)
Industry, innovation and infrastructure
Openalex Percentile: Top 15%
Machine Learning in Healthcare
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.